• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用集落形成单位-粒细胞巨噬细胞(CFU-GM)测定法预测新型抗肿瘤药物Yondelis(ET-743)的人体最大耐受剂量。

Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).

作者信息

Gómez Susana G, Bueren Juan A, Faircloth Glynn, Albella Beatriz

机构信息

PharmaMar, S.A. Polígono Industrial La Mina, Avda de los Reyes, 1. 28770 Colmenar Viejo, Madrid, Spain.

出版信息

Toxicol In Vitro. 2003 Oct-Dec;17(5-6):671-4. doi: 10.1016/s0887-2333(03)00139-5.

DOI:10.1016/s0887-2333(03)00139-5
PMID:14599461
Abstract

Acute cytotoxic exposure causes decreases in bone marrow progenitors that precedes the neutrophil nadir. Experiments in animal models reveal a relationship between the reduction in granulocyte-macrophage progenitors (CFU-GM) and the decrease in absolute neutrophil count [Toxicol. Pathol. 21 (1993) 241]. Recently, the prevalidation of a model for predicting acute neutropenia by the CFU-GM assay has been reported [Toxicol. In Vitro 15 (2001) 729]. The model was based on prediction of human MTD by adjusting the animal-derived MTD for the differential sensitivity between CFU-GM from animal species and humans. In this study, this model has been applied on a new antitumoral drug, Yondelis (Ecteinascidin; ET-743). Preclinical studies showed that hematotoxicity was the main side effect in mice, being the MTD of 600 microg/m2 [Drugs Future 21 (1996) 1155]. The sensitivity of myeloid progenitors was higher in mice than in humans, with IC90 values of 0.69+/-0.22 nM and 1.31+/-0.21 nM for murine and human CFU-GMs respectively. This study predicts a human MTD of 1145 microg/m2. The reported human MTD of ET-743 given as a 24-h continuous infusion every 3 weeks is 1800 microg/m2 [J. Clin. Oncol. 19 (2001) 1256]. Since our predicted MTD is within fourfold of the actual MTD (the interspecies variation in tolerated dose due to differences in clearance rates, metabolism pathways and infusion rate) the result confirms the profit of the prediction model.

摘要

急性细胞毒性暴露会导致骨髓祖细胞减少,且该减少发生在中性粒细胞计数最低点之前。动物模型实验揭示了粒细胞 - 巨噬细胞祖细胞(CFU - GM)减少与绝对中性粒细胞计数降低之间的关系[《毒理病理学》21卷(1993年)第241页]。最近,已有关于通过CFU - GM测定法预测急性中性粒细胞减少模型的预验证报告[《毒理学体外研究》15卷(2001年)第729页]。该模型基于通过调整动物源性最大耐受剂量(MTD)来预测人类MTD,以考虑动物物种和人类CFU - GM之间的差异敏感性。在本研究中,此模型已应用于一种新的抗肿瘤药物Yondelis(埃博霉素;ET - 743)。临床前研究表明,血液毒性是小鼠的主要副作用,MTD为600μg/m²[《药物未来》21卷(1996年)第1155页]。小鼠髓系祖细胞的敏感性高于人类,小鼠和人类CFU - GM的IC90值分别为0.69±0.22 nM和1.31±0.21 nM。本研究预测人类MTD为1145μg/m²。每3周进行一次24小时连续输注时,已报道的ET - 743人类MTD为1800μg/m²[《临床肿瘤学杂志》19卷(2001年)第1256页]。由于我们预测的MTD在实际MTD的四倍以内(由于清除率、代谢途径和输注速率差异导致的种间耐受剂量变化),结果证实了该预测模型的益处。

相似文献

1
Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).使用集落形成单位-粒细胞巨噬细胞(CFU-GM)测定法预测新型抗肿瘤药物Yondelis(ET-743)的人体最大耐受剂量。
Toxicol In Vitro. 2003 Oct-Dec;17(5-6):671-4. doi: 10.1016/s0887-2333(03)00139-5.
2
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.集落形成单位-粒细胞巨噬细胞(CFU-GM)检测法在预测急性药物性中性粒细胞减少症中的应用:一项验证骨髓抑制性异生物最大耐受剂量(MTD)预测模型的国际盲法试验。
Toxicol Sci. 2003 Oct;75(2):355-67. doi: 10.1093/toxsci/kfg188. Epub 2003 Jul 25.
3
Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.
Toxicol In Vitro. 2001 Dec;15(6):729-40. doi: 10.1016/s0887-2333(01)00085-6.
4
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.Yondelis(埃博霉素-743;ET-743)每21天以1小时或3小时静脉输注方式给药,用于实体瘤患者的I期和药代动力学研究。
Eur J Cancer. 2003 Sep;39(13):1842-51. doi: 10.1016/s0959-8049(03)00458-1.
5
In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay.血液毒性的体外试验:通过CFU-GM试验预测药物诱导的骨髓抑制
Altern Lab Anim. 2002 Dec;30 Suppl 2:75-9. doi: 10.1177/026119290203002S11.
6
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.基于机制的曲贝替定(ET-743,Yondelis)诱导中性粒细胞减少的药代动力学/药效学荟萃分析。
Clin Pharmacol Ther. 2008 Jan;83(1):130-43. doi: 10.1038/sj.clpt.6100259. Epub 2007 Jun 27.
7
Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells.双功能烷化剂比泽司汀对人、犬和鼠类骨髓祖细胞的骨髓毒性作用。
Cancer Chemother Pharmacol. 1996;39(1-2):143-9. doi: 10.1007/s002800050550.
8
Prevalidation of the rat CFU-GM assay for in vitro toxicology applications.大鼠 CFU-GM assay 用于体外毒理学应用的预验证。
Altern Lab Anim. 2010 May;38(2):105-17. doi: 10.1177/026119291003800212.
9
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.两种海洋来源的抗肿瘤药物ET-743和阿普立定对人骨髓造血祖细胞的体外毒性:与临床结果的比较
Eur J Cancer. 2002 Jul;38(10):1395-404. doi: 10.1016/s0959-8049(01)00245-3.
10
Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.
Eur J Cancer. 2003 Mar;39(5):675-83. doi: 10.1016/s0959-8049(02)00812-2.

引用本文的文献

1
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.理解纳米药物的体外和体内免疫毒性测试之间的相关性。
J Control Release. 2013 Dec 10;172(2):456-66. doi: 10.1016/j.jconrel.2013.05.025. Epub 2013 Jun 3.
2
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).基于两阶段模型的癌症 I 期剂量递增试验设计:以巴拉斯替尼(AZD1152)I 期计划为例的评估。
Invest New Drugs. 2012 Aug;30(4):1519-30. doi: 10.1007/s10637-011-9694-5. Epub 2011 May 28.
3
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.
两阶段基于模型的临床试验设计,优化新型抗癌药物的 I 期开发。
Invest New Drugs. 2010 Feb;28(1):61-75. doi: 10.1007/s10637-008-9216-2. Epub 2009 Feb 6.
4
Novel Marine Compounds: Anticancer or Genotoxic?新型海洋化合物:抗癌还是具有基因毒性?
J Biomed Biotechnol. 2004;2004(2):93-98. doi: 10.1155/S1110724304307060.